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that all APCS species with acyl groups ranging from C14 to 
C24 were elevated in NPC1 plasma. PPCS is also elevated in 
both central and peripheral tissues of the NPC1 cat model.  
Identification of APCS structures provide an opportunity 
for broader exploration of the roles of these novel lipids 
in NPC1 disease pathology and diagnosis.—Sidhu, R., Y. 
Mondjinou, M. Qian, H. Song, A. B. Kumar, X. Hong, F-F. 
Hsu, D. J. Dietzen, N. M. Yanjanin, F. D. Porter, E. Berry-
Kravis, C. H. Vite, M. H. Gelb, J. E. Schaffer, D. S. Ory, and 
X. Jiang. N-acyl-O-phosphocholineserines: structures of a 
novel class of lipids that are biomarkers for Niemann-Pick 
C1 disease. J. Lipid Res. 2019. 60: 1410–1424.
Supplementary key words Niemann-Pick disease type C • mass spec-
trometry • structural identification • lysoSM-509
Niemann-Pick disease type C (NPC) is a rare neurovis-
ceral disorder caused by mutations of NPC1 (95% of NPC 
cases) (1) or NPC2 (2) and characterized by accumulation 
of unesterified cholesterol and glycosphingolipids in late 
endosomes/lysosomes (3). The impaired lipid trafficking 
is associated with neuron loss and defective myelination, 
leading to neuroinflammatory and neurodegenerative 
disease pathology (4). NPC1 disease shows substantial 
Abstract Niemann-Pick disease type C1 (NPC1) is a fatal, 
neurodegenerative, cholesterol storage disorder. With new 
therapeutics in clinical trials, there is an urgency to improve 
diagnostics and monitor therapeutic efficacy with biomark-
ers. In this study, we sought to define the structure of an 
unknown lipid biomarker for NPC1 with [M + H]+ ion at 
m/z 509.3351, previously designated as lysoSM-509. The 
structure of N-palmitoyl-O-phosphocholineserine (PPCS) 
was proposed for the lipid biomarker based on the results 
from mass spectrometric analyses and chemical derivatiza-
tions. As no commercial standard is available, authentic PPCS 
was chemically synthesized, and the structure was confirmed 
by comparison of endogenous and synthetic compounds 
as well as their derivatives using liquid chromatography- 
tandem mass spectrometry (LC-MS/MS). PPCS is the most 
abundant species among N-acyl-O-phosphocholineserines 
(APCS), a class of lipids that have not been previously de-
tected in biological samples. Further analysis demonstrated 
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heterogeneity in age of onset and systemic, neurological, 
and psychiatric signs and symptoms (5). The heterogeneity 
of disease presentation and lack of specific symptoms com-
plicate diagnosis, leading to an average diagnostic delay of 
4–5 years (6). As currently available treatments, such as mi-
glustat (7) and 2-hydroxypropyl--cyclodextrin (8–10), can 
only stabilize or slow disease progression, early initiation of 
treatment prior to onset of neurologically symptomatic dis-
ease is essential.
In recent years, diagnosis of NPC1 disease has been 
greatly facilitated by discovery of sensitive and specific bio-
markers that are elevated in blood from NPC patients. The 
most promising of these include oxysterols (11–23), lyso-
sphingomyelin (24), N-(3,5,6-trihydroxy-cholan-24-oyl)
glycine (designated as bile acid B) (25, 26), and an unknown 
lipid (lysoSM-509) (27–31). The oxysterol, cholestane-
3,5,6-triol, is the most widely disseminated biomarker 
and has been implemented on multiple platforms in 
50 laboratories worldwide. In combination with genetic 
analyses, oxysterols have become a first line diagnostic test 
(32). lysoSM-509 showed similar diagnostic potential to 
cholestane-3,5,6-triol (27), though application of this 
biomarker has been limited because its structure is unknown. 
Herein, we performed structural analysis of lysoSM-509 to 
show that it is N-palmitoyl-O-phosphocholineserine (PPCS), 
the most abundant species of a class of lipids, N-acyl-O-
phosphocholineserines (APCSs). To the best of our knowl-
edge, this is the first description of this lipid class.
MATERIALS AND METHODS
Human subjects
Human studies adhered to the principles of the Declaration of 
Helsinki, as well as to Title 45, US Code of Federal Regulations, 
Part 46, Protection of Human Subjects. Informed consent was 
obtained from the human subjects or their representatives. NPC1 
plasma and dried blood spot samples were obtained from the 
National Institutes of Health and Rush University Medical Center. 
All NPC1 and NPC1 carrier dried blood spots were de-identified 
and collected from previously diagnosed patients and obligate 
heterozygotes, respectively. Normal plasma and dried blood 
spots were obtained from anonymized residual samples at St. 
Louis Children’s Hospital. Whole blood, plasma, red blood cells, 
and white blood cells were collected from four heathy adult vol-
unteers. Collection and analysis of de-identified human samples 
were approved by the institutional review boards at Washington 
University, Eunice Kennedy Shriver National Institute of Child 
Health and Human Development, and Rush University Medical 
Center.
Experimental animals
BALB/c Npcnih (Npc1/) mice were obtained from Jackson 
Laboratories (Bar Harbor, ME) and were maintained in a breed-
ing colony at Washington University. NPC1 cats were raised in 
the animal colony of the School of Veterinary Medicine at the 
University of Pennsylvania under National Institutes of Health 
and US Department of Agriculture guidelines for the care and 
use of animals in research. Serum/plasma, liver, and brain sam-
ples were collected from 24- to 25-week-old cats and 7-week-old 
mice. Experimental procedures were approved by the Washington 
University and University of Pennsylvania Animal Studies Com-
mittees and were conducted in accordance with the US Depart-
ment of Agriculture Animal Welfare Act and the Public Health 
Service Policy for the Humane Care and Use of Laboratory 
Animals.
Profiling of lysoSM-509 in human plasma and dried blood 
spots
lysoSM-509 was extracted from plasma samples (50 l) and 
dried blood spot discs (3 mm) and submitted to LC-MS/MS. 
The detailed protocols are described in the supplemental 
information.
lysoSM-509 structure identification
LC-HRMS of endogenous lysoSM-509 and synthetic PPCS. The lys-
oSM-509 isolated from plasma was reconstituted in methanol 
and submitted to the LC-high-resolution MS (LC-HRMS) assay 
described in the supplemental information.
Hydrogen/deuterium exchange experiment. The hydrogen/deu-
terium (H/D) exchange experiment of isolated lysoSM-509 
was conducted on a Shimadzu Prominence HPLC system cou-
pled with the Applied Biosystems/MDS Sciex 4000QTRAP 
mass spectrometer operating in positive multiple reaction 
monitoring (MRM) mode, as described in the supplemental 
information.
Derivatization. Derivatization of lysoSM-509, including methyl 
esterification, acylation, ozonolysis, and alkaline degradation, and 
LC-MS/MS analysis of derivatized lysoSM-509 and synthetic PPCS 
are described in the supplemental information.
Synthesis of PPCS, d5-PPCS, and potential precursors for 
PPCS bioanalysis
N-palmitoyl-l-serine methyl ester (2a). To a solution of N-succin-
imidyl palmitate (1.35 g, 3.82 mmol, 1 eq) in dichloromethane 
(15 ml) was added l-serine methyl ester hydrochloride (1a) (1.23 
g, 7.93 mmol, 2.1 eq) and triethylamine (1.21 ml, 8.73 mmol, 2.28 
eq), and the mixture was stirred at room temperature overnight. 
The solution was loaded on a silica column and purified with 
chromatography (dichloromethane/methanol, 10/1) to give 2a 
(1.19 g, 87%), mp: 86–87°C. 1H NMR (400 MHz, CDCl3)  6.58 
(d, J = 6.7 Hz, 1H), 4.51 (dt, J = 3.6, 6.7 Hz, 1H), 3.92 (dd, J = 3.6, 
11.1, 1H), 3.86 (d, J = 11.1, 1H), 3.73 (s, 3H), 2.22 (t, J = 6.9 Hz, 
2H), 1.641.54 (m, 2H), 1.271.18 (m, 24H), 0.83 (t, J = 6.9, 
3H). 13C NMR (100 MHz, CDCl3)  173.98, 171.65, 63.23, 54.59, 
52.68, 36.48, 31.82, 29.70, 29.67, 29.66, 29.64, 29.52, 29.37, 29.36, 
29.26, 25.59, 22.69, 14.12.
(S)-N-palmitoyl-O-H-phosphonate-serine methyl ester (3a). A solu-
tion of imidazole (2.38 g, 35 mmol, 25 eq) in dichloromethane 
(25 ml) was cooled to 10°C, followed by addition of phosphorus 
trichloride (0.611 ml, 7 mmol, 5 eq) and triethylamine (2.92 ml, 
21 mmol, 15 eq). The reaction mixture was stirred for 30 min 
at 10°C. A solution of compound 2a (500 mg, 1.4 mmol, 1 eq) 
in dichloromethane (20 ml) was added dropwise to the reaction 
mixture using a syringe pump over a period of 90 min. After the 
addition, the mixture was stirred for 40 min further and quenched 
by addition of water (10 ml). The resulting solution was stirred for 
an additional period of 5 min. The organic layer was washed with 
brine (10 ml). The aqueous phase was extracted with tetrahydro-
furan until it became a clear solution. The combined organic 
phases were dried with sodium sulfate and concentrated. The resi-
due was dried over phosphorus pentoxide under high vacuum 
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(S)-N-palmitoyl-O-phosphocholineserine methyl ester (5a). A mix-
ture of crude 3a (1.4 mmol, 1 eq) and choline tetraphenylborate 
(1.18 g, 2.8 mmol, 2 eq) was dried by evaporation with anhydrous 
pyridine (10 ml). The mixture was dissolved in pyridine (10 ml), 
and 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide 
(0.775 g, 4.2 mmol, 3 eq) was added. The resulting mixture was 
stirred for 15 min to give 4a. Iodine (0.427 g, 1.68 mmol, 1.2 eq) 
dissolved in pyridine (3 ml) and water (0.2 ml) was added and the 
mixture was stirred for 10 min. The solution was washed with 5% 
(w/v) aqueous solution of sodium bisulfite until the color faded. 
The mixture was concentrated to give crude 5a, which was con-
firmed as PPCS methyl ester by LC-MS/MS. The 5a was com-
pletely degraded to decomposition products 1 and 2 by alkaline 
hydrolysis at room temperature for 60 h.
N-palmitoyl-l-serine tert-butyl ester (2b). The 2b was prepared as 
a white solid from N-succinimidyl palmitate (1.3 g, 3.68 mmol, 
1 eq), l-serine tert-butyl ester hydrochloride (1b) (1.53 g, 7.73 
mmol, 2.1 eq), and triethylamine (1.17 ml, 8.4 mmol, 2.28 eq) 
according to the procedure described for the preparation of 2a 
(1.45 g, 99%), mp: 64–65°C. 1H NMR (400 MHz, CDCl3)  
6.58 (d, J = 6.7 Hz, 1H), 4.51 (dt, J = 3.5, 6.7 Hz, 1H), 3.85 (d, 
J = 3.5 Hz, 2H), 2.22 (t, J = 6.9 Hz, 2H), 1.661.55 (m, 2H), 
1.45 (s, 9H), 1.271.18 (m, 24H), 0.83 (t, J = 6.9, 3H). 13C NMR 
(100 MHz, CDCl3)  173.82, 169.59, 82.54, 63.71, 55.30, 55.27, 
36.47, 31.84, 29.61, 29.58, 29.54, 29.41, 29.28, 29.21, 27.90, 
25.53, 22.60, 14.02.
(S)-N-palmitoyl-O-H-phosphonate-serine tert-butyl ester (3b). The 3b 
was prepared from 2b (0.94 g, 2.35 mmol, 1 eq), imidazole (4 g, 
58.75 mmol, 25 eq), phosphorus trichloride (1.03 ml, 11.75 
mmol, 5 eq), and triethylamine (4.9 ml, 35.25 mmol, 15 eq) 
according to the procedure described for the preparation of 
3a. The crude 3b was used directly in the next step without 
purification.
(S)-N-palmitoyl-O-phosphocholineserine tert-butyl ester (5b). The 5b 
was prepared from crude 3b (prepared as above), choline tetrap-
henylborate (1.99 g, 4.7 mmol, 2 eq), 2-chloro-5,5-dimethyl-1,3,2-
dioxaphosphorinane 2-oxide (1.3 g, 7.05 mmol, 3 eq), iodine 
(0.716 g, 2.82, 1.2 eq), and water (0.4 ml) according to the proce-
dure described for the preparation of 5a. The crude 5b was used 
directly in the next step without purification.
(S)-N-palmitoyl-O-phosphocholineserine. A suspension of crude 
5b (prepared as above) in trifluoroacetic acid (27 ml) and chloro-
form (27 ml) was stirred at room temperature for 1 day and evap-
orated to dryness. The residue was chromatographed on C18 
silica (methanol-water, 7/3). The PPCS was further purified with 
chromatography on silica with chloroform-methanol-water 
(50:49:1) to give a white solid (225 mg, 19% overall yield from 
2b), mp: 220–221°C. 1H NMR (400 MHz, CD3OD)  4.87 (s, 1H), 
4.36 (d, 1H, J = 1.1 Hz), 4.22 (m, 2H), 4.07 (m, 1H), 3.58 (dd, 2H, 
J = 4.3, 6.2 Hz), 3.26 (d, 1H, J = 1.1 Hz), 3.17 (s, 9H), 2.22 (t, 2H, 
J = 7.6 Hz), 1.57 (m, 2H), 1.23 (m, 24H), 0.85 (t, 2H, J = 7.6 Hz). 
13C NMR (100 MHz, CD3OD)  176.03, 175.64, 68.08, 68.03, 
60.58, 60.53, 56.73, 56.63, 54.87, 54.84, 54.80, 37.47, 33.24, 30.97, 
30.93, 30.83, 30.72, 30.67, 30.65, 27.03, 23.90, 14.62.
N-d5-palmitoyl-l-serine tert-butyl ester (2c). The 2c was prepared 
as a white solid from N-succinimidyl-d5-palmitate (0.67 g, 1.87 
mmol, 1 eq), l-serine tert-butyl ester hydrochloride (1b) (0.776 g, 
3.93 mmol, 2.1 eq), and triethylamine (0.593 ml, 4.26 mmol, 
2.28 eq) according to the procedure described for the prepa-
ration of 2a (0.71 g, 93%), mp: 64–65°C. 1H NMR (400 MHz, 
CDCl3)  6.53 (d, J = 6.7 Hz, 1H), 4.53 (dt, J = 3.5, 6.7 Hz, 1H), 
3.88 (d, J = 3.5 Hz, 2H), 3.22 (s, br, 1H), 2.23 (t, J = 6.9 Hz, 2H), 
1.661.56 (m, 2H), 1.47 (s, 9H), 1.271.18 (m, 22H). 13C NMR 
(100 MHz, CDCl3)  173.83, 169.58, 82.69, 63.94, 55.35, 36.51, 
31.57, 29.63, 29.60, 29.56, 29.43, 29.29, 29.26, 29.21, 27.93, 
25.54.
(S)-N-d5-palmitoyl-O-H-phosphonate-serine tert-butyl ester (3c). The 
3c was prepared from 2c (0.71 g, 1.75 mmol, 1 eq), imidazole 
(2 g, 29.75 mmol, 25 eq), phosphorus trichloride (0.76 ml, 
8.75 mmol, 5 eq), and triethylamine (3.65 ml, 26.25 mmol, 
15 eq) according to the procedure described for the preparation 
of 3a. The crude 3c was used directly in the next step without 
purification.
(S)-N-d5-palmitoyl-O-phosphocholineserine tert-butyl ester (5c). The 
5c was prepared from crude 3c (prepared as above), choline tetra-
phenylborate (1.48 g, 3.5 mmol, 2 eq), 2-chloro-5,5-dimethyl-1,3,2-
dioxaphosphorinane 2-oxide (0.97 g, 5.25 mmol, 3 eq), iodine 
(0.533 g, 2.1, 1.2 eq), and water (0.4 ml) according to the proce-
dure described for the preparation of 5a. The crude 5c was used 
directly in the next step without purification.
(S)-N-d5-palmitoyl-O-phosphocholineserine. The (S)-N-d5-palmitoyl- 
O-phosphocholineserine (d5-PPCS) was prepared as a white 
solid from crude 5c (prepared as above), trifluoroacetic acid 
(20 ml), and chloroform (20 ml) according to the procedure 
described for the preparation of PPCS (85 mg, 9% overall yield 
from 2c), mp: 221–223°C. 1H NMR (400 MHz, CD3OD)  4.87 
(s, 1H), 4.36 (d, 1H, J = 1.1 Hz), 4.22 (m, 2H), 4.07 (m, 1H), 3.58 
(dd, 2H, J = 4.3, 6.2 Hz), 3.26 (d, 1H, J = 1.1 Hz), 3.17 (s, 9H), 2.22 
(t, 2H, J = 7.6 Hz), 1.57 (m, 2H), 1.23 (m, 22H). 13C NMR (100 
MHz, CD3OD)  175.98, 174.78, 67.50, 67.44, 60.65, 60.60, 55.88, 
55.80, 54.87, 54.83, 54.80, 37.26, 32.95, 30.98, 30.96, 30.83, 30.71, 
30.61, 27.05.
Synthesis of N-d5-palmitoylserine (6), N-d5-palmitoylphosphati-
dylserine [N-d5-palmitoyl 1,2-distearoyl-sn-glycero-3-phospho- 
l-serine (7)], N-d5-palmitoyl-phytosphingosine phosphocholine 
(8), N-d5-palmitoyl-phosphoserine (9), and O-phosphocholine-d3- 
l-serine (10) is described in the supplemental information.
Generation of PPCS in heathy human blood and 
quantification of PPCS in tissues from NPC animal 
models
The generation of PPCS in heathy human blood and quantifi-
cation of PPCS in tissues from NPC animal models are described 
in the supplemental information.
Profiling of APCS in human plasma
Profiling of APCS in human plasma is described in the supple-
mental information.
Statistical methods
Normally distributed data were analyzed using Student’s t-test 
or ANOVA. Non-normally distributed data was analyzed using the 
Mann-Whitney test or the Kruskal-Wallis test.
RESULTS
Elucidation of the structure of lysoSM-509
To elucidate the structure of lysoSM-509, we collected 
the HPLC fractions containing lysoSM-509 from NPC1 
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analysis and chemical derivatization. As it was difficult 
to isolate sufficient (at least 10 g) pure endogenous lys-
oSM-509 from limited NPC plasma samples for acceptable 
NMR spectra due to its low abundance and the complex 
plasma lipid components, NMR analysis was not per-
formed. Our strategy for determination of the structure of 
lysoSM-509 is outlined in Fig. 1.
MS. High-resolution mass spectrometric analysis of lys-
oSM-509 in the positive mode showed an abundant ion at 
an accurate m/z value of 509.3351 for [M+H]+ corre-
sponding to the formula C24H50O7N2P (calculated mass, 
509.3350) with mass errors less than 1 mDa (Fig. 2A). The 
[M+Na]+ ion at m/z 531.3168 (C24H49O7N2PNa; calculated 
mass, 531.3170) and the [M+2Na-H]+ ion at m/z 553.2986 
(C24H48O7N2PNa2; calculated mass, 553.2989) were also 
observed in positive mode (Fig. 2A), and the [M-H] ion at 
m/z 507.3205 (C24H48O7N2P; calculated mass, 507.3205) 
appeared in negative mode (Fig. 2B), suggesting that there 
were two acidic groups in lysoSM-509. The molecular for-
mula C24H50O7N2P indicated that the degree of unsatura-
tion in lysoSM-509 was two.
The high-resolution and accurate-mass product ion 
spectrum (Fig. 2C) of the [M+H]+ ion acquired with higher 
energy collisional dissociation (HCD) contained product 
ions at m/z 184.0730, 124.9997, 104.1072, and 86.0968, cor-
responding to protonated phosphocholine (C5H15NO4P
+; 
calculated mass, 184.0733), protonated ethylene phos-
phate (C2H6O4P
+; calculated mass, 124.9998), choline 
(C5H14NO
+; calculated mass, 104.1070), vinyltrimethylam-
monium (C5H12N
+; calculated mass, 86.0964), respectively, 
indicating that lysoSM-509 contains a phosphocholine 
group (33). Very low abundant product ions at m/z  
326.2697 (C19H36NO3
+; calculated mass, 326.2690; resulted 
from neutral loss of a phosphocholine), m/z 271.1045 
(C8H20N2O6P
+; calculated mass, 271.1053), and m/z 225.0996 
(C7H18N2OP
+; calculated mass, 225.0999) were also ob-
served. Fragmentation of the [M+Na]+ and [M+2Na-H]+ 
ions provided information only related to phosphocho-
line. The product ions of the [M+Na]+ ion include m/z 
472.2430 ([M+Na-N(CH3)3]
+, C21H40NO7PNa; calculated 
mass, 472.2435), m/z 348.2511 ([M+Na-phosphocholine]+, 
C19H35NO3Na
+; calculated mass, 348.2509), m/z 206.0552 
([phosphocholine+Na]+, C5H14NO4PNa
+; calculated mass, 
206.0553), m/z 146.9819 ([ethylene phosphate+Na]+, 
C2H5O4PNa
+; calculated mass, 146.9818), and m/z 86.0964 
(vinyltrimethylammonium, C5H12N
+; calculated mass, 




culated mass, 494.2254), m/z 370.2325 ([M+2Na-H-
phosphocholine]+, C19H34NO3Na2
+; calculated mass, 
370.2329), m/z 228.0370 ([phosphocholine+2Na-H]+, 
C5H13NO4PNa2
+; calculated mass, 228.0372), m/z 206.0553 
([phosphocholine+Na]+, C5H14NO4PNa
+; calculated mass, 
206.0553), m/z 168.9638 ([ethylene phosphate-H+2Na]+, 
C2H4O4PNa2
+; calculated mass, 168.9637), and m/z 86.0964 
(vinyltrimethylammonium, C5H12N
+; calculated mass, 
86.0964) (Fig. 2E). The HCD spectrum of the [M-H] 
ion shows product ions at m/z 324.2551 ([M-H-phos-
phocholine], C19H34NO3
; calculated mass, 324.2544), 
m/z 280.2653 (C18H34NO
; calculated mass, 280.2646), m/z 
237.2228 (C16H29O




lated mass, 168.0435), m/z 122.9856 ([ethylene phosphate-
H], C2H4O4P
; calculated mass, 122.9856), m/z 96.9699 
(H2PO4
; calculated mass, 96.9699), and m/z 78.9592 
(PO3
; calculated mass, 78.9591) (Fig. 2F). Although prod-
uct ions at m/z 271.1045 and 225.0996 from fragmentation 
of protonated lysoSM-509 and m/z 280.2653 and 237.2228 
ions from fragmentation of deprotonated lysoSM-509 pro-
vided structural information for other than phosphocholine, 
the structure of lysoSM-509 could not be assigned without 
more information.
Although the full mass scan of lysoSM-509 offered a 
good quality spectrum, the H/D exchange experiment us-
ing the full mass scan did not provide sufficient sensitivity 
as the signals were distributed over additional isotope 
peaks, and the amount of HPLC-isolated lysoSM-509 was 
limited. MRM was used to detect the deuterium exchange-
associated peaks, in which MRM transitions from deute-
rium exchanged lysoSM-509 to protonated phosphocholine 
were used. A number of possible deuterated precursors in-
cluded [M+H]+ at m/z 509, [M+D]+ at m/z 510, [M-H+2D]+ 
at m/z 511, [M-2H+3D]+ at m/z 512, [M-3H+4D]+ at m/z 
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Fig. 2. Identification of the structure of lysoSM-509. A: High-resolution mass spectrum of endogenous lys-
oSM-509 in positive ion mode. B: High-resolution mass spectrum of endogenous lysoSM-509 in negative ion 
mode. C: High-resolution product ion spectrum of the [M+H]+ ion of endogenous lysoSM-509. D: High-
resolution product ion spectrum of the [M+Na]+ ion of endogenous lysoSM-509. E: High-resolution product 
ion spectrum of the [M+2Na-H]+ ion of endogenous lysoSM-509. F: High-resolution product ion spectrum 
of the [M-H] ion of endogenous lysoSM-509. G: H/D exchange of endogenous lysoSM-509 detected with 
MRM. The [M-2H+3D]+ ion at m/z 512 shows the maximum intensity. H: Product ion spectrum of the 
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513, and [M-4H+5D]+ at m/z 514. Protonated phosphocho-
line was used to construct the MRM transitions. There are 
two labile hydrogens in protonated phosphocholine, and 
deuterated phosphocholine was also included (supple-
mental Table S1). The number of exchangeable hydrogens 
is the difference between the mass of the exchanged peak 
with maximum intensity and the mass of the [M+D]+ at m/z 
510. The [M-2H+3D]+ at m/z 512 showed the maximum in-
tensity, showing that there were two exchangeable protons 
in lysoSM-509 (Fig. 2G).
Chemical derivatization. Treatment of lysoSM-509 with 
HCl in methanol gave a methyl ester with mass upshift of 
14 Da (Fig. 2H), suggesting that lysoSM-509 bore a carbox-
ylic group. The fragmentation of the [M+H]+ ion of the 
methyl ester produced the same product ions as those in 
lysoSM-509. The toleration of acidic conditions by lys-
oSM-509 indicated that there were no acid-labile groups, 
such as a vinyl ether or an imine. No acetylated products 
were observed when lysoSM-509 was treated with acetic an-
hydride/pyridine, suggesting that it did not have nucleo-
philes such as amino and alcohol groups. lysoSM-509 
survived the treatment with ozone, suggesting that it lacked 
a carbon-carbon double bond. Treatment of lysoSM-509 
with sodium hydroxide in methanol-water (95:5) led to 
decomposition. Two decomposition products (decomposi-
tion product 1, N-palmitoylserine; decomposition product 
2, N-palmitoyl-O-methylserine) were confirmed only after 
authentic PPCS was synthesized.
Proposed structure of lysoSM-509. We proposed that the 
phosphocholine was connected to the other moiety of 
lysoSM-509 via a phosphate bond, similar to phosphatidyl-
choline and sphingomyelin, because protonated phospho-
choline is also the most abundant product ion in 
fragmentation of [M+H]+ of phosphatidylcholine and 
sphingomyelin. Besides the phosphocholine and carbox-
ylic groups, the remaining moiety of lysoSM-509 had a for-
mula of C18H35ON, in which the oxygen and nitrogen were 
most likely part of an amide bond. The presence of the 
carboxylic acid and the amide groups in lysoSM-509 was in 
agreement with the degree of unsaturation of two, no 
amine or alcohol group, and two exchangeable protons. 
After assignment of phosphocholine, carboxylic acid, and 
the amide groups, the remaining C17H34 was composed of 
saturated alkyl groups. lysoSM-509 was temporarily assigned 
as PPCS.
The structure of PPCS was supported by the proposed 
fragmentation pathways to all the product ions from the 
[M+H]+ ion (Fig. 3A). The m/z 326 ion was formed by intra-
molecular attack of the carboxylate to the phosphocholine, 
resulting in loss of a phosphocholine. Loss of palmitoyl as a 
ketene gave the m/z 271 ion. The 1,4-elimination led to loss 
of a CO2 and a palmitaldehyde to yield the m/z 225 ion. 
The dominant product ion at m/z 184 was generated via 
six-membered ring H-transfer as a major pathway and 
1,2-elimination as a minor pathway, which were supported 
by the H/D exchange experiment. The m/z 184 ion also 
was generated from the m/z 271 ion after loss of a CO2 and 
a vinylamine via 1,4-elimination. Further neutral loss of tri-
methylamine, metaphosphoric acid, and phosphoric acid 
from the m/z 184 ion yielded the m/z 125, 104, and 86 ions, 
respectively.
Unlike other phosphocholine lipids, such as phosphati-
dylcholine and sphingomyelin, that produce the [M-15] 
ion by neutral loss of CH3X via collisional decomposition 
of the adduct anion [M+X] at the orifice, where X can be 
chloride, formate, and acetate (34), PPCS readily formed 
the [M-H] ion due to the carboxylic acid group. The 
structure of PPCS was also supported by fragmentation of 
the [M-H] ion. The 1,2-elimination of a phosphocholine 
afforded the m/z 324 ion. The 1,4-elimination led to loss of 
a CO2 and a phosphocholine to yield the m/z 280 ion, 
which underwent 1,4-elimination of a vinylamine to give 
the m/z 237 ion. Formation of the m/z 168 ion was probably 
via attack of methyl on choline by the carboxylate followed 
by 1,2-elimination to yield demanyl phosphate at m/z 168, 
from which neutral loss of N-vinyldimethylamine and 
2-dimethylaminoethanol gave phosphate (m/z 97) and 
metaphosphate (m/z 79), respectively. The m/z 123 ion was 
generated after neutral loss of the lactone and trimethyl-
amine from the [M-H] ion (Fig. 3B).
Synthesis of PPCS
In order to confirm the structure of PPCS, we devised a 
synthetic plan to generate PPCS. Accordingly, we prepared 
N-palmitoyl-l-serine methyl ester (2a) and converted it to 
N-palmitoyl-O-phosphocholineserine methyl ester (5a) via 
H-phosphonate intermediates 3a and 4a using a modified 
literature procedure (35) (Fig. 4A). The nonhydroscopic 
choline tetraphenylborate (36) was used for installation of 
the H-phosphocholine in 4a. However, base hydrolysis of 
the methyl ester in 5a led to two decomposition products, 
N-palmitoylserine (decomposition product 1) and N-palmi-
toyl-O-methylserine (decomposition product 2), in which 
the phosphocholine group was lost. Although base hydro-
lysis of a typical sphingomyelin cleaves the phosphoester 
bond on the choline side to yield ceramide-1-phosphate 
(37), the phosphoester bond at the serine side of PPCS was 
cleaved. This unusual cleavage may be due to the intra-
molecular participation of the carboxylate group, which at-
tacks carbon-3 of serine to give a four-membered ring 
lactone. The lactone was unstable due to ring strain and 
readily opened by attack of hydroxide and methoxide to 
afford decomposition products 1 and 2 (Fig. 4B). This issue 
was addressed in a revised approach, in which the methyl 
ester-protecting group was changed to a tert-butyl ester. 
Following the same procedure as for 5a, N-palmitoyl-O-
phosphocholineserine tert-butyl ester (5b) was prepared. 
Removal of the tert-butyl ester in 5b with trifluoroacetic 
acid afforded PPCS. The crude synthetic intermediates, 
3a/b to 5a/b, were used directly in the next step without 
isolation, which significantly simplified the synthetic pro-
cedure. PPCS was purified with reverse phase solid phase 
extraction followed by chromatography on silica. Similarly, 
d5-PPCS was also prepared as an internal standard for 
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Confirmation of the structure of lysoSM-509
The structure of lysoSM-509 was confirmed by com-
parative LC-MS/MS analysis of endogenous and synthesized 
authentic compound, its methyl esters, and decomposition 
products under basic conditions. Endogenous lysoSM-509 
(Fig. 5A, B) and its methyl ester (Fig. 5C) showed the 
same retention time and product ion scan spectra as 
synthetic PPCS and its methyl ester, respectively. The de-
composition products of endogenous lysoSM-509 were 
detected with MRM of all the abundant product ions from 
Fig. 3. Proposed fragmentation pathways for PPCS. A: Proposed fragmentation pathway for the [M+H]+ ion. B: Proposed fragmentation 
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collision-induced dissociation of the decomposition prod-
ucts of synthetic PPCS (supplemental Fig. S1), because 
they were not sufficiently abundant to provide good qual-
ity product ion spectra. The decomposition products of 
endogenous lysoSM-509 matched with those of synthetic 
PPCS (Fig. 5D). All of the results verified that lysoSM-509 
is PPCS.
Generation of PPCS in human blood
To explore the ability of PPCS to serve as a biomarker for 
newborn screening of NPC1 disease, we compared new-
born controls (n = 211), NPC1 carriers (n = 10), and NPC1 
subjects (n = 10). Compared with newborn controls, PPCS 
in dried blood spots from NPC1 subjects was elevated only 
2.75-fold with overlap between two groups (Fig. 6A), whereas 
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PPCS was elevated 24-fold in NPC1 plasma compared with 
control plasma (Fig. 6B). The overlap between PPCS in 
NPC1 and control dried blood spots has also been reported 
in an earlier report (28).
PPCS in blank Whatman 903 newborn screening cards 
was undetectable. To investigate the basis of attenuated 
PPCS in dried blood spots compared with plasma, we ex-
amined PPCS in whole blood and dried blood spots from 
the same normal subjects. Compared with whole blood, 
PPCS in dried blood spots increased 8.3-fold (Fig. 6C). 
To determine whether components in the Whatman 903 
newborn screening card promoted PPCS production in 
whole blood, we agitated whole blood with 3 mm disks 
from a blank newborn screening card for 18 h at room 
temperature. The PPCS levels in blood with newborn 
screening card disks did not change (not shown), suggest-
ing that PPCS was generated during the drying process. 
We further compared the PPCS in red blood cells, white 
blood cells, and plasma with dried red blood cell spots, 
dried white blood cell spots, and dried plasma spots, 
respectively. Although PPCS was not detectable in red blood 
cells and white blood cells, PPCS levels in dried red blood 
cell spots and white blood cell spots ranged from 60 to 
83 ng/ml red blood cells and from 62 to 72 ng/dried white 
blood cells from 3 ml whole blood, respectively (Fig. 6D, E). 
Similarly, PPCS in dried plasma spots increased 4-fold 
compared with plasma levels (Fig. 6F). These results indi-
cate that a PPCS precursor is present in all the blood com-
ponents and can be converted into PPCS during drying.
We spiked several potential precursors to explore the 
biosynthetic route of the PPCS, including N-d5-palmitoyl-
serine (6), N-d5-palmitoylphosphatidylserine [N-d5-palmitoyl 
1,2-distearoyl-sn-glycero-3-phospho-l-serine (7)], N-d5-pal-
mitoyl-phytosphingosine phosphocholine (8), N-d5-pal-
mitoyl-phosphoserine (9), O-phosphocholine-d3-l-serine 
(10), and d5-palmitic acid (11) into blood and prepared 
dried blood spots. However, neither d5-PPCS nor d3-PPCS 
was observed in the dried blood spots, indicating that 
Fig. 5. Confirmation of the structure of lysoSM-509. A: Chromatograms (detected by product ion scan) and high resolution product ion 
spectra of the [M+H]+ ions of endogenous lysoSM-509 and synthetic PPCS. B: Chromatograms (detected by product ion scan) and high-
resolution product ion spectra of the [M-H] ions of endogenous lysoSM-509 and synthetic PPCS. C: Chromatograms (detected by product 
ion scan) and product ion spectra of the [M+H]+ ions of endogenous lysoSM-509 methyl ester and synthetic PPCS methyl ester. D: Decom-
position products 1 and 2 from synthetic PPCS and endogenous lysoSM-509. Decomposition product 1 was detected in seven MRM transi-
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Fig. 6. PPCS in dried blood spot and plasma samples and its generation in blood during the drying process. A: PPCS in newborn control 
(n = 211), NPC1 carrier (n = 10), and NPC1 (n = 10) dried blood spot samples. Data are presented as mean ± 95% confidence interval (CI) 
concentration. P < 0.0001 for lysoSM-509 in NPC1 versus controls and NPC1 carriers. B: PPCS in control (n = 25) and NPC1 (n = 26) plasma 
samples. Data are presented as mean ± 95% CI peak area. P < 0.0001 for lysoSM-509 in NPC1 versus controls. C: Elevation of PPCS in dried 
blood spots (n = 5) compared with whole blood (n = 5). The dried blood spots and whole blood from the same subject are shown in the same 
color. Data are presented as mean ± 95% CI. P < 0.0001 for dried blood spots versus whole blood. D: Elevation of PPCS in dried red blood 
cell spots (n = 4) compared with red blood cells (n = 4). The dried red blood cell spots and red blood cells from the same subject are shown 
in the same color. Data are presented as mean ± 95% CI. P < 0.0001 for dried red blood cell spots versus red blood cells. E: Elevation of PPCS 
in dried white blood cell spots (n = 4) compared with white blood cells (n = 4). The dried white blood cell spots and white blood cells from 
the same subject are shown in the same color. Data are presented as mean ± 95% CI. P < 0.0001 for dried white blood cell spots versus white 
blood cells. F: Elevation of PPCS in dried plasma spots (n = 4) compared with plasma (n = 4). The dried plasma spots and plasma from the 
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none of these compounds appeared to be direct precur-
sors of PPCS (Fig. 7).
Elevation of PPCS in serum, brain, and liver from a NPC1 
cat model
To understand whether PPCS is elevated in the central 
nervous system or peripheral organs in NPC1 disease, we 
analyzed plasma/serum, brain, and liver from NPC1 mouse 
and cat models. While PPCS was undetectable in plasma 
and tissues from mouse (data not shown), it was signifi-
cantly elevated in serum, brain, and liver in NPC1 cats com-
pared with control and NPC1 carrier cats (Fig. 8). This 
result demonstrated that PPCS accumulates in both cen-
tral and peripheral tissues and highlighted the species dif-
ference between mouse and cat/human with respect to 
metabolic pathways involved in generation of PPCS.
APCS in human plasma
The structure of PPCS [APCS(16:0)] suggested that it 
was one of multiple species in the APCS lipid family. We 
also analyzed other species in plasma using MRM transi-
tions from theoretical masses of [M+H]+ ions of APCS 
to m/z 184 (Table 1). The APCS species included 
N-myristoyl- [APCS(14:0)], N-palmitoyl- [APCS(16:0)], 
N-palmitoleoyl- [APCS(16:1)], N-stearoyl- [APCS(18:0)], 
N-oleoyl- [APCS(18:1)], N-arachidoyl- [APCS(20:0)], 
N-behenoyl- [APCS(22:0)], N-lignoceroyl- [APCS(24:0)], 
and tetracosenoyl-O-phophocholineserines [APCS(24:1)]. 
Like PPCS, all other APCS species were elevated in NPC1 
plasma (Fig. 9).
DISCUSSION
Diagnosis of NPC1 disease is challenging due to the rare 
nature of the disorder, the genetic heterogeneity, and the 
initially nonspecific clinical presentation. The advent of 
NPC1 disease-specific biochemical markers has shortened 
the time to diagnosis of patients with a high clinical suspi-
cion of NPC1, in which the disease is significantly advanced. 
Nonetheless, biomarkers that can be applied to the general 
population or for newborn screening could further im-
prove early identification of the disease. One such marker, 
lysoSM-509, is currently under evaluation as a NPC1 diag-
nostic marker (27), and LC-MS/MS diagnostic assays based 
on lysoSM-509 have been reported (28–31). However, 
quantification of lysoSM-509 using these assays has not 
been reliable due to lack of information regarding the 
Fig. 7. Hypothetical pathways for the formation of PPCS. Neither d5-PPCS nor d3-PPCS were formed in dried blood spots from potential 
precursors, including N-d5-palmitoylserine (6), N-d5-palmitoylphosphatidylserine (N-d5-palmitoyl 1,2-distearoyl-sn-glycero-3-phospho-l-ser-
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molecular identity of the biomarker. As no authentic stan-
dard was available, lysosphingomyelin was used as a calibra-
tor. The mass spectrometric responses of lysoSM-509 and 
lysosphingomyelin and their matrix effects are different, 
and it is always best to use a chemically identical but isotopi-
cally substituted lysoSM-509 internal standard. In the pres-
ent study, we identified the structure of lysoSM-509 by 
accurate mass measurements, tandem mass spectra, chemi-
cal derivatization, and comparison to an authentic syn-
thetic standard. Unexpectedly, we found that lysoSM-509 is 
not a lysosphingomyelin species, as previously proposed 
(27). Rather, the biomarker is PPCS, a member of a unique 
class of lipids designated as APCS. With the structure of ly-
soSM-509 in hand, it is now possible to synthesize and use a 
proper internal standard for its accurate quantification.
To the best of our knowledge, APCS lipids have not pre-
viously been described. A series of related serine com-
pounds have been reported in biological samples, including 
O-serine phosphoethanolamine (38), N-acylserines (39), 
N-acyl lysophosphatidylserines (40), and N-acyl phosphati-
dylserines (39, 41). Serine phosphoethanolamine was 
identified with 31PNMR in dystrophic chicken (38). N-acyl 
phosphatidylserines were originally identified in sheep red 
blood cells by infrared spectrum, elemental analysis, and 
hydrolysis products (41). Later, N-acyl phosphatidylserines 
and N-acylserines were identified in human brain with the 
palmitoyl and stearoyl forms being most abundant when 
analyzed by MS, and their levels change in the frontal 
cortex in schizophrenia (39). N-acyl phosphatidylserines 
were also detected with LC-MS/MS in pig brain, mouse 
RAW264.7 macrophage tumor cells, and yeast (42). N-ara-
chidonoyl serine is an activator of large conductance Ca2+-
activated K+ channels (43) with vasodilatory properties 
(44), which also alters the activation of N-type Ca2+ chan-
nels in sympathetic neurons (45). N-acyl lysophosphati-
dylserines were identified in mouse brain with mass 
spectrometric lipidomics, and ABHD4 is a general N-acyl 
phospholipid hydrolase to convert N-acyl phosphatidylser-
ines to N-acyl lysophosphatidylserines (40). N-palmitoyl-
serine phosphoric acid was synthesized as inhibitor of lipid 
phosphatidate receptors (46). O-phosphocholine-l-serine 
has not been reported previously, and we synthesized 
O-phosphocholine-d3-l-serine (10) as a potential precursor 
to study biosynthesis of PPCS in this study.
Although we observed artifactual generation of PPCS in 
blood components from normal subjects, including whole 
blood, red blood cells, white blood cells, and plasma, when 
they were dried on newborn screening cards, PPCS is an 
endogenous lipid that is stable in blood and plasma under 
normal experimental conditions. The PPCS level in whole 
blood did not change at room temperature after the 
blood was agitated with 3 mm disks from a blank newborn 
Fig. 8. Elevation of PPCS in serum, brain, and liver from NPC1 
cat model. A: PPCS in sera from control (n = 8), NPC1 carrier 
(n = 3), and NPC1 (n = 7) cats. Data are presented as mean with SD. 
P < 0.0001 for NPC1 versus control and NPC carriers. B: PPCS in 
livers from control (n = 9), NPC1 carrier (n = 5), and NPC1 (n = 5) 
cats. Data are presented as mean with SD. P < 0.0001 for NPC1 
versus control and NPC carriers. C: PPCS in brains from control 
(n = 10), NPC1 carrier (n = 5), and NPC1 (n = 6) cats. Data are 
presented as mean with SD. P < 0.0001 for NPC1 versus control 
and NPC carriers.
TABLE 1. MRM transitions for APCS
MRM Transition APCS Precursor Ion (m/z) Product Ion (m/z)
1 APCS(14:0) 481.3 184
2 APCS(16:0) 509.3 184
3 APCS(16:1) 507.3 184
4 APCS(18:0) 537.3 184
5 APCS(18:1) 535.3 184
6 APCS(20:0) 565.3 184
7 APCS(22:0) 593.3 184
8 APCS(24:0) 621.3 184
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screening card for 18 h. We also developed a validated 
plasma assay for PPCS that will be published in a separate 
article, and found that the PPCS level in plasma was un-
changed at room temperature for 24 h. Artifactual gen-
eration of PPCS in blood on newborn screening cards 
significantly reduced the difference in PPCS levels between 
NPC1 and normal subjects. As a result, we observed signifi-
cant overlap between NPC1 and newborn controls, consis-
tent with an earlier report (28), thus rendering PPCS of 
limited utility for NPC newborn screening based on detec-
tion of the metabolite in dried blood spots. Although our 
effort to elucidate the biosynthesis of APCS using blood 
drying on newborn screening cards in this study was not 
successful, our work has eliminated a number of possibili-
ties and provided a foundation for future study. Under-
standing the biosynthesis and regulation of APCS and its 
involvement in NPC and acid sphingomyelinase deficiency, 
in which plasma PPCS levels are increased (27), may un-
cover the potential therapeutic targets for these two stor-
age diseases.
The authors would like to thank Dr. Douglas Covey for helpful 
discussion of the synthesis of PPCS. The authors are grateful to 
the National Niemann-Pick Disease Foundation for their 
assistance in obtaining samples from NPC1 and NPC1 carrier 
subjects and express their appreciation to the families and 
patients who participated in this study.
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